In patients with acute heart failure, treatment with serelaxin, a recombinant form of human relaxin 2, did not reduce the incidence of cardiovascular death or worsening heart failure. Click to show full abstract
In patients with acute heart failure, treatment with serelaxin, a recombinant form of human relaxin 2, did not reduce the incidence of cardiovascular death or worsening heart failure.
Keywords:
serelaxin treatment;
death;
treatment;
reduce incidence;
treatment reduce
Journal Title: Nature Reviews Cardiology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Nature Reviews Cardiology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!